You searched for dabigatran - MPR

Your search for dabigatran returned 15 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

MPR First Report remove

Your search for dabigatran returned 15 results

Sort Results:

Relevant Recent
American College of Cardiology 2011

Dabigatran Etexilate vs. Warfarin in Different Types of Atrial Fibrillation

A subgroup analysis from the RE-LY trial has demonstrated that in patients with atrial fibrillation (AF), twice-daily dabigatran etexilate has better efficacy and lower rates of major bleeding when compared with warfarin, as reported at ACC.11, the American College of Cardiology's 60th Annual Scientific Session.
American College of Cardiology 2013

Similar Bleeding and Thrombotic Complication Rates Between Dabigatran and Rivaroxaban

At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, Anil Rajendra, MD, from the Medical University of South Carolina, in Charleston, SC, presented data showing similar bleeding and thrombotic complication rates at the time of atrial fibrillation ablation (AFA) in patients anticoagulated with dabigatran and rivaroxaban. Dr. Rajendra and colleagues determined that rivaroxaban has an acceptable safety profile for AFA.
American College of Cardiology 2013

Dabigatran Safe and Effective Post-Atrial Fibrillation Ablation

At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, leading cardiologists presented that the use of dabigatran following ablation for atrial fibrillation resulted in no major post-procedural complications.
ASH 2010

Issues in Thrombosis Management and Anticoagulation

Novel oral anticoagulants, that do not require the laboratory monitoring associated with warfarin therapy, may alter the landscape of venous thromboembolism treatment and stroke prevention in atrial fibrillation, according to a study presented at the 52nd American Society of Hematology Meeting and Exposition.
American College of Cardiology 2011

Dabigatran Superior to Warfarin in Patients with Atrial Fibrillation and Lower CHA2DS2-VASc Scores

Dabigatran 150mg was superior to warfarin and dabigatran 110mg was noninferior to warfarin for preventing stroke in patients with atrial fibrillation (AF) regardless of CHA2DS2-VASc scores, as shown by the results of a subgroup analysis of the RE-LY trial presented today at ACC.11, the American College of Cardiology's 60th Annual Scientific Session.
American College of Cardiology 2011

Supratherapeutic Dabigatran Does Not Prolong the QTc Interval

Supratherapeutic plasma levels of dabigatran etexilate do not prolong QTc intervals of the electrocardiogram (ECG), as reported from a study presented at ACC.11, the American College of Cardiology's 60th Annual Scientific Session.